The novel SARS-CoV-2 (COVID-19) became a pandemic on 11 March 2020. The epidemiological picture is constantly evolving, and on 13 May, 4,170,424 cases and 287,399 confirmed deaths have been reported (WHO Report). People with COVID-19 infection may show several symptoms, including fever, cough, nausea, vomiting, dyspnea, myalgia, fatigue, arthralgia, headache, diarrhea, and rarely arthritis \[[@CR1]\]. COVID-19 clinical features range from asymptomatic patients to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction \[[@CR2], [@CR3]\]. Influenza symptoms are associated with a cascade of inflammatory mediators. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels in plasma and upper respiratory secretions directly correlate with the magnitude of viral replication, fever, and respiratory and systemic symptoms, including musculoskeletal clinical manifestations \[[@CR4], [@CR5]\] Musculoskeletal symptoms such as fatigue, myalgia and arthralgia are common COVID-19 symptoms, but their prevalence has not yet been systematically investigated \[[@CR6], [@CR7]\]. We collected the published clinical data of the past 5 months to ascertain the prevalence of musculoskeletal symptoms and epidemiological characteristics published worldwide in COVID-19 patients.

Data were tabulated using Microsoft Excel^TM^ 2020 V.16.34. The value was showed as mean ± SD. Student *t* test was used to reveal musculoskeletal symptoms between the total sample. To assess the incidence for each clinical variable, frequency analysis was performed. Regression analysis (*R*^*2*^) was used to examine correlations between the total sample and musculoskeletal symptoms extracted. The level of significant was set at *p* \< 0.05.

The relevant reference and the data collected from the included articles are indicated in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Table 1DemographicsStudy (year)No. of patientsSexAge (mean SD or median IQR)Study designCountryZheng et al. \[[@CR8]\]99M 51F 4849.40 (SD 18.45)Retrospective single centerChinaLei et al. \[[@CR9]\]34M 14F 2055 (43--63)Retrospective single centerChinaMo et al. \[[@CR10]\]155M 86F 6954 (42--66)Retrospective single centerChinaQian et al. \[[@CR11]\]91M 37F 5450 (54--80)Retrospective multi-centerChinaMa et al. \[[@CR12]\]37M 20F 1762 (59--70)Retrospective single centerChinaJin et al. \[[@CR13]\]651M 331F 24646.0 (32--60)Retrospective multi-centerChinaZheng et al. \[[@CR14]\]161M 80F 8145.0 (33.5--57)Retrospective single centerChinaWang et al. \[[@CR15]\]80M 31F 4939.0 (32--48.5)Retrospective multi-center (electronic database)ChinaChen et al. \[[@CR16]\]203M 108F 9554.0 (20--91)Retrospective single centerChinaZhou et al. \[[@CR17]\]21M 13F 866.1 (SD 13.94)Retrospective single centerChinaLo et al. \[[@CR18]\]10M 3F 754 (27--64)Retrospective single centerChinaHuang et al. \[[@CR19]\]41M 30F 1149.0 (41.0--58.0)Prospective multi-center (electronic database)ChinaZhang et al. \[[@CR20]\]645M 328F 31746.65 (SD 13.82)Retrospective multi-center (electronic database)ChinaChen et al. \[[@CR21]\]249M 126F 12351.0 (36--64)Retrospective single centerChinaFeng et al. \[[@CR22]\]476M 271F 20553.0 (40--64)Retrospective multi-centerChinaChen et al. \[[@CR23]\]274M 171F 10362.0 (44--70)Retrospective single centerChinaZhang et al. \[[@CR24]\]140M 71F 6957.0 (25--87)Retrospective multi-centerChinaLian et al. \[[@CR25]\]788M 407F 38141.15 (SD 11.38)Retrospective multi-center (electronic database)ChinaCai et al. \[[@CR26]\]298M 145F 15347.5 (33--61)Retrospective single centerChinaWan et al. \[[@CR27]\]135M 72F 6347.0 (36--55)Retrospective single centerChinaCao et al. \[[@CR28]\]102M 53F 4954.0 (37--67)Retrospective single centerChinaWang et al. \[[@CR29]\]339M 166F 17369.0 (65--76)Retrospective single centerChinaXu et al. \[[@CR30]\]62M 36F 2741.0 (32--52)Retrospective single centerChinaZhou et al. \[[@CR31]\]191M 119F 7256.0 (46--67)Retrospective multi-center cohort studyChinaWu et al. \[[@CR32]\]201M 128F 7351.0 (43--60)Retrospective single center cohort studyChinaDu et al. \[[@CR33]\]85M 62F 2365.8Retrospective multi-centerChinaWang et al. \[[@CR34]\]69M 32F 3742.0 (35--62)Retrospective single centerChinaGuan et al. \[[@CR35]\]1099M 640F 45947.0 (35--58)Retrospective multi-centerChinaGoyal et al. \[[@CR36]\]393M 238F 15562.2 (49--74)Retrospective multi-centerUSAZhang et al. \[[@CR37]\]28M 17F 1165.0 (56--70)Retrospective single centerChinaChen et al. \[[@CR38]\]118M 0F 11831.0 (28--34)Retrospective single centerChinaWang et al. \[[@CR39]\]1012M 524F 48850.0 (39--58)Retrospective multi-centerChinaXia et al. \[[@CR40]\]10M 6F 456.5Retrospective single centerChinaLiang et al. \[[@CR41]\]1590M 904F 67448.9 (SD 16.3)Retrospective multi-centerChinaDai et al. \[[@CR42]\]234M 136F 9844.6Retrospective single centerChinaLi et al. \[[@CR43]\]25M 12F 1345.6Retrospective single centerChinaChu et al. \[[@CR44]\]54M 36F 1839Retrospective single centerChinaQi et al. \[[@CR45]\]70M 39F 3139.5Retrospective multi-centerChinaGodaert et al. \[[@CR46]\]17M 8F 986.5Retrospective single centerFranceYe et al. \[[@CR47]\]5M 2F 330.0Retrospective single centerChinaHuang et al. \[[@CR48]\]22M 6F 1622.0 (16.0--23.0)Retrospective single centerChinaTian et al. \[[@CR49]\]262M 127F 13547.5Retrospective single centerChinaHuang et al. \[[@CR50]\]34M 14F 2056.2Retrospective single centerChinaXia et al. \[[@CR51]\]20M 13F 71.5Retrospective single centerChinaZhao et al. \[[@CR52]\]101M 56F 4544.44Retrospective multi-centerChinaXu et al. \[[@CR53]\]51M 25F 2641.6Retrospective single centerChinaLi et al. \[[@CR54]\]548M 279F 26960.0 (48--69)Retrospective single centerChinaXu et al. \[[@CR55]\]90M 39F 5150.0 (18--86)Retrospective single centerChinaLei et al. \[[@CR56]\]119M 77F 4249.0 (SD 13.6)Retrospective multi-centerChinaPung et al. \[[@CR57]\]17M 7F 1040.0Retrospective single centerSingaporeXu et al. \[[@CR71]\]50M 29F 2142.3Retrospective single centerChinaEscalera-Antezana et al. \[[@CR58]\]12M 6F 636.5Retrospective single centerBoliviaLechien et al. \[[@CR59]\]417M 154F 26336.9 (SD 11.4)Retrospective multi-centerEuropeDong et al. \[[@CR72]\]11M 5F 640.3Retrospective single centerChinaTotal: 5412.046M 6427 (54%)F 5597 (46%)52.13Table 2Musculoskeletal symptomsStudy (year)No. of patientsFatigue (nr/%)Arthralgia/Myalgia (nr/%)Zheng et al. \[[@CR37]\]9972 (73%)12 (12%)Lei et al. \[[@CR36]\]3425 (73.5%)11 (32.4%)Mo et al. \[[@CR60]\]15560 (73.2)50 (61.0%)Qian et al. \[[@CR61]\]9140 (43.96%)5 (5.49%)Ma et al. \[[@CR62]\]374 (10.8%)4 (10.8%)Jin et al. \[[@CR10]\]651119 (18.2%)/Zheng et al. \[[@CR11]\]16164 (39.8%)18 (11.2%)Wang et al. \[[@CR12]\]8028 (35%)19 (23.75%)Chen et al. \[[@CR13]\]20316 (7.9%)54 (26.6)Zhou et al. \[[@CR14]\]215 (23.8%)2 (9.5%)Lo et al. \[[@CR15]\]10/3 (30%)Huang et al. \[[@CR16]\]4118 (44%)/Zhang et al. \[[@CR17]\]645118 (18.3%)71 (11%)Chen et al. \[[@CR18]\]24939 (15.7%)/Feng et al. \[[@CR19]\]476/59 (12.4%)Chen et al. \[[@CR20]\]274137 (50%)60 (22%)Zhang et al. \[[@CR58]\]140105 (75%)/Lian et al. \[[@CR47]\]788139 (17.6%)91 (11.5%)Cai et al. \[[@CR21]\]29813 (4.3%)/Wan et al. \[[@CR22]\]135/44 (32.5%)Cao et al. \[[@CR9]\]10256 (54.9%)35 (34.3)Wang et al. \[[@CR32]\]339135 (39.9%)16 (4.7%)Xu et al. \[[@CR26]\]62/32 (52%)Zhou et al. \[[@CR27]\]19144 (23%)29 (15%)Wu et al. \[[@CR29]\]20165 (32.3%)/Du et al. \[[@CR33]\]8550 (58.8%)14 (16.5%)Wang et al. \[[@CR35]\]6929 (42%)21 (30%)Guan et al. \[[@CR33]\]1099419 (38%)164 (15%)Goyal et al. \[[@CR46]\]393/94 (24%)Zhang et al. \[[@CR24]\]2818 (64%)4 (14%)Chen et al. \[[@CR34]\]11819 (16%)/Wang et al. \[[@CR41]\]1012/170 (17%)Xia et al. \[[@CR38]\]103 (30%)/Liang et al. \[[@CR39]\]1590680 (43%)278 (17%)Dai et al. \[[@CR40]\]23431 (13%)21 (9%)Li et al. \[[@CR41]\]2517 (68%)/Chu et al. \[[@CR42]\]549 (17%)3 (6%)Qi et al. \[[@CR43]\]70/12 (17%)Godaert et al. \[[@CR7]\]1710 (59%)/Ye et al. \[[@CR28]\]55 (100%)/Huang et al. \[[@CR44]\]225 (23%)4 (18%)Tian et al. \[[@CR45]\]26269 (26%)/Huang et al. \[[@CR8]\]34/22 (65%)Xia et al. \[[@CR48]\]201 (5%)/Zhao et al. \[[@CR49]\]101/17 (17%)Xu et al. \[[@CR25]\]512 (4%)8 (16%)Li et al. \[[@CR51]\]548258 (47%)111 (20%)Xu et al. \[[@CR52]\]9019 (21%)25 (28%)Lei et al. \[[@CR54]\]119/18 (15%)Pung et al. \[[@CR6]\]17/5 (29%)Xu et al. \[[@CR55]\]508 (16%)8 (16%)Escalera-Antezana et al. \[[@CR59]\]12/5 (42%)Lechien et al. \[[@CR57]\]417129 (31%)246 (59%)Dong et al. \[[@CR56]\]112 (18%)1 (9%)Total: 54Tot: 12,0463085 (25.6%)1866 (15.5%)

Data on 12,046 patients (54% male and 46% females) were available. The number of patients in the selected studies ranged from 5 to 1590 patients (223 ± 312 patients). The sex ratio (male to female) was 1:15, and the overall average of patients was 52.13 years. The majority of the studies arose from China, mainly from Wuhan; one was from Singapore \[[@CR57]\], two from Europe \[[@CR46], [@CR59]\], one from the USA \[[@CR36]\], and one from Bolivia \[[@CR58]\]. Musculoskeletal symptoms were present from the earliest stage of the viral illness and were reported in patients necessitating intensive care in the end stage of the condition. The total prevalence of fatigue symptom was 25.6% (*R*^2^ =0.56; *p* value = 0.004), while the prevalence of arthralgia and/or myalgia was 15.5% (*R*^2^ = 0.66; *p* value = 0.001; Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Relationships of fatigue and arthralgia/myalgia on all patients

Eight studies reported a prevalence higher than 50% of patients with fatigue \[[@CR8], [@CR9], [@CR24], [@CR25], [@CR28], [@CR37], [@CR46], [@CR47]\], while three studies reported higher values for arthralgia/myalgia symptoms \[[@CR50], [@CR53], [@CR59]\]. The prevalence of musculoskeletal symptoms in studies from Europe reached high values \[[@CR46], [@CR59]\]; Lechien et al., for example, reported on 417 COVID-19 patients from 12 European hospitals and found myalgia in 246 (59%) and arthralgia in 129 (31%) of these patients \[[@CR59]\].

Clinical presentation of COVID-19 ranges from absence of symptoms to severe pneumonia. Fever, dry cough and fatigue are common symptoms, as indeed are myalgia and arthralgia \[[@CR6], [@CR53]\]. Most of the articles are retrospective single center studies: data were collected in a non-homogeneous way, especially regarding comorbidities, lifestyle habits, and severity of the illness. Based on our work, we cannot state, for example, whether children and younger patients less commonly present musculoskeletal symptoms at onset \[[@CR63]\]. Most studies originate from China, which is not surprising, and it is not clear whether the prevalence of musculoskeletal symptoms at onset is influenced by socio-geographical factors \[[@CR64]\]. The most common symptoms in patients with mild to moderate clinical presentation of the condition are fever, fatigue, and dry cough, followed by other symptoms including headache, nasal congestion, sore throat, myalgia, and arthralgia \[[@CR65], [@CR66]\].

The evidence on the central role of inflammation during COVID-19 infection underlines the need to block this inflammatory cascade \[[@CR30], [@CR60]--[@CR62], [@CR67]--[@CR70]\]. The presence of musculoskeletal symptoms is worrying: there is a high rate of use, especially in the middle age and elderly population, of NSAIDs. The fact that patients therefore report musculoskeletal symptoms is even more worrying because it may imply that the inflammatory reactions overcome the anti-inflammatory effect of such drugs.

Clinical features have to be analyzed deeply, especially considering the new evidences on COVID-19. Musculoskeletal symptoms should be married with laboratory findings, such as inflammatory and infection-related parameters (Interleukin-6, Procalcitonin, C-reactive protein). Understandably, the involvement of the musculoskeletal system has not been deeply investigated during this pandemic, but synovial and muscle biopsy, and joint fluid analysis, for example, should clarify how extensive the attack of the virus on the whole of the human body is. Until now, no report has been published on the presence of COVID-19 in the skeletal muscles, joint, or bones. The musculoskeletal symptoms are only anecdotally attributed to indirect effects, mainly arising from inflammatory and/or immune response, but other mechanisms can be hypothesized, such as direct damage by the virus on the endothelium or peripheral nerves. These findings could help to plan specific rehabilitation protocols in COVID-19 patients.

As a new infectious disease, it is particularly important to underline the clinical features of COVID-19, especially in the early stage of the illness, to help clinicians to individuate and isolate patients earlier, and then minimize its diffusion. From the onset of the symptoms and to the most severe stages of COVID-19 disease, musculoskeletal symptoms, including myalgia, arthralgia, and fatigue, are a nearly constant presence. It is still unclear how the effects of COVID-19 on the musculoskeletal system are mediated.
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